Page last updated: 2024-08-07 16:36:36
Vasopressin V1a receptor
A vasopressin V1a receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P37288]
Synonyms
V1aR;
AVPR V1a;
Antidiuretic hormone receptor 1a;
Vascular/hepatic-type arginine vasopressin receptor
Research
Bioassay Publications (60)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 1 (1.67) | 18.7374 |
| 1990's | 6 (10.00) | 18.2507 |
| 2000's | 19 (31.67) | 29.6817 |
| 2010's | 31 (51.67) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
Compounds (31)
Drugs with Inhibition Measurements
Drugs with Activation Measurements
Drugs with Other Measurements
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 21, Issue:19, 2011
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.Journal of medicinal chemistry, , Oct-04, Volume: 50, Issue:20, 2007
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Khusimol, a non-peptide ligand for vasopressin V1a receptors.Journal of natural products, , Volume: 57, Issue:10, 1994
Oral oxytocin antagonists.Journal of medicinal chemistry, , Sep-23, Volume: 53, Issue:18, 2010
Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.Journal of medicinal chemistry, , Nov-16, Volume: 43, Issue:23, 2000
1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.Journal of medicinal chemistry, , Nov-10, Volume: 38, Issue:23, 1995
Khusimol, a non-peptide ligand for vasopressin V1a receptors.Journal of natural products, , Volume: 57, Issue:10, 1994
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.Journal of medicinal chemistry, , Oct-25, Volume: 55, Issue:20, 2012
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.Bioorganic & medicinal chemistry, , Volume: 7, Issue:8, 1999
New analgesic drugs derived from phencyclidine.Journal of medicinal chemistry, , Volume: 24, Issue:5, 1981
Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007
Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 17, Issue:21, 2007
(4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 15, Issue:22, 2005
Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.Bioorganic & medicinal chemistry letters, , Jun-07, Volume: 14, Issue:11, 2004
Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.Bioorganic & medicinal chemistry letters, , Feb-24, Volume: 13, Issue:4, 2003
Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.Bioorganic & medicinal chemistry letters, , Nov-04, Volume: 12, Issue:21, 2002
The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.Bioorganic & medicinal chemistry letters, , Apr-17, Volume: 10, Issue:8, 2000
4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.Bioorganic & medicinal chemistry letters, , Jul-05, Volume: 9, Issue:13, 1999
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.Journal of medicinal chemistry, , Jul-02, Volume: 41, Issue:14, 1998
Benzodiazepine Derivatives as Potent Vasopressin VJournal of medicinal chemistry, , 07-14, Volume: 65, Issue:13, 2022
Synthesis and Characterization of New VJournal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.Bioorganic & medicinal chemistry, , Volume: 7, Issue:8, 1999
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors.Bioorganic & medicinal chemistry, , 08-01, Volume: 27, Issue:15, 2019
Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.Bioorganic & medicinal chemistry letters, , 02-01, Volume: 28, Issue:3, 2018
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.Bioorganic & medicinal chemistry, , 07-15, Volume: 26, Issue:11, 2018
LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.Journal of medicinal chemistry, , 10-11, Volume: 61, Issue:19, 2018
Potent and selective oxytocin receptor agonists without disulfide bridges.Bioorganic & medicinal chemistry letters, , 06-01, Volume: 27, Issue:11, 2017
Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.Journal of medicinal chemistry, , Mar-12, Volume: 58, Issue:5, 2015
New, potent, and selective peptidic oxytocin receptor agonists.Journal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014
Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 19, Issue:3, 2009
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
Hybrid peptide-small molecule oxytocin analogs are potent and selective agonists of the oxytocin receptor.Bioorganic & medicinal chemistry letters, , 02-01, Volume: 28, Issue:3, 2018
Potent and selective oxytocin receptor agonists without disulfide bridges.Bioorganic & medicinal chemistry letters, , 06-01, Volume: 27, Issue:11, 2017
New, potent, and selective peptidic oxytocin receptor agonists.Journal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.Bioorganic & medicinal chemistry, , 07-15, Volume: 26, Issue:11, 2018
New, potent, and selective peptidic oxytocin receptor agonists.Journal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014
Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.Journal of medicinal chemistry, , Oct-25, Volume: 55, Issue:20, 2012
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.Journal of medicinal chemistry, , Apr-28, Volume: 54, Issue:8, 2011
New, potent, selective, and short-acting peptidic V1a receptor agonists.Journal of medicinal chemistry, , Jul-14, Volume: 54, Issue:13, 2011
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.Journal of medicinal chemistry, , Oct-04, Volume: 50, Issue:20, 2007
Discovery and optimization of highly ligand-efficient oxytocin receptor antagonists using structure-based drug design.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 19, Issue:3, 2009
The discovery of GSK221149A: a potent and selective oxytocin antagonist.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 18, Issue:1, 2008
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.Journal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
New, potent, and selective peptidic oxytocin receptor agonists.Journal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.Journal of medicinal chemistry, , Apr-22, Volume: 47, Issue:9, 2004
LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.Journal of medicinal chemistry, , 10-11, Volume: 61, Issue:19, 2018
Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.Journal of medicinal chemistry, , Feb-25, Volume: 53, Issue:4, 2010
Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 17, Issue:21, 2007
Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 16, Issue:4, 2006
Oral oxytocin antagonists.Journal of medicinal chemistry, , Sep-23, Volume: 53, Issue:18, 2010
Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.Journal of medicinal chemistry, , Feb-25, Volume: 53, Issue:4, 2010
Identification of potent and selective oxytocin antagonists. Part 2: further investigation of benzofuran derivatives.Bioorganic & medicinal chemistry letters, , May-20, Volume: 12, Issue:10, 2002
Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.Bioorganic & medicinal chemistry letters, , May-03, Volume: 9, Issue:9, 1999
1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.Journal of medicinal chemistry, , Nov-10, Volume: 38, Issue:23, 1995
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHBioorganic & medicinal chemistry, , 01-15, Volume: 25, Issue:2, 2017
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.Bioorganic & medicinal chemistry, , Apr-15, Volume: 24, Issue:8, 2016
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.European journal of medicinal chemistry, , Volume: 63, 2013
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.Bioorganic & medicinal chemistry, , May-15, Volume: 21, Issue:10, 2013
Carbon-11 N-methyl alkylation of L-368,899 and in vivo PET imaging investigations for neural oxytocin receptors.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 23, Issue:3, 2013
Oral oxytocin antagonists.Journal of medicinal chemistry, , Sep-23, Volume: 53, Issue:18, 2010
Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 21, Issue:6, 2011
The characterization of a novel V1b antagonist lead series.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 21, Issue:1, 2011
Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.Journal of medicinal chemistry, , Jan-26, Volume: 55, Issue:2, 2012
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors.Journal of medicinal chemistry, , 04-11, Volume: 62, Issue:7, 2019
New, potent, and selective peptidic oxytocin receptor agonists.Journal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014
Synthesis and Characterization of New VJournal of medicinal chemistry, , 07-22, Volume: 64, Issue:14, 2021
New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 30, Issue:18, 2020
Recent Advances in Scaffold Hopping.Journal of medicinal chemistry, , 02-23, Volume: 60, Issue:4, 2017
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.Journal of medicinal chemistry, , Mar-12, Volume: 58, Issue:5, 2015
Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.Journal of medicinal chemistry, , 10-11, Volume: 61, Issue:19, 2018
Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Enables
This protein enables 6 target(s):
| Target | Category | Definition |
|---|
| vasopressin receptor activity | molecular function | Combining with vasopressin to initiate a change in cell activity. [GOC:ai] |
| protein kinase C binding | molecular function | Binding to protein kinase C. [GOC:jl] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| peptide hormone binding | molecular function | Binding to a peptide with hormonal activity in animals. [GOC:jl, ISBN:0198506732] |
| V1A vasopressin receptor binding | molecular function | Binding to a V1A vasopressin receptor. [GOC:mah, GOC:nln] |
| peptide binding | molecular function | Binding to a peptide, an organic compound comprising two or more amino acids linked by peptide bonds. [GOC:jl] |
Located In
This protein is located in 3 target(s):
| Target | Category | Definition |
|---|
| endosome | cellular component | A vacuole to which materials ingested by endocytosis are delivered. [ISBN:0198506732, PMID:19696797] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| endocytic vesicle | cellular component | A membrane-bounded intracellular vesicle formed by invagination of the plasma membrane around an extracellular substance. Endocytic vesicles fuse with early endosomes to deliver the cargo for further sorting. [GOC:go_curators, PMID:19696797] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
Involved In
This protein is involved in 28 target(s):
| Target | Category | Definition |
|---|
| maternal aggressive behavior | biological process | Aggressive behavior of a female to protect her offspring from a threat. [GOC:hjd] |
| positive regulation of systemic arterial blood pressure | biological process | The process that increases the force with which blood travels through the systemic arterial circulatory system. [GOC:mtg_cardio] |
| generation of precursor metabolites and energy | biological process | The chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and any process involved in the liberation of energy from these substances. [GOC:jl] |
| activation of phospholipase C activity | biological process | The initiation of the activity of the inactive enzyme phospolipase C as the result of The series of molecular signals generated as a consequence of a G protein-coupled receptor binding to its physiological ligand. [GOC:dph, GOC:mah, GOC:tb, PMID:8280098] |
| positive regulation of cytosolic calcium ion concentration | biological process | Any process that increases the concentration of calcium ions in the cytosol. [GOC:ai] |
| negative regulation of female receptivity | biological process | Any process that stops, prevents or reduces the receptiveness of a female to male advances. [GOC:bf, PMID:11092827] |
| grooming behavior | biological process | The specific behavior of an organism relating to grooming, cleaning and brushing to remove dirt and parasites. [GOC:jl, GOC:pr] |
| blood circulation | biological process | The flow of blood through the body of an animal, enabling the transport of nutrients to the tissues and the removal of waste products. [GOC:mtg_heart, ISBN:0192800825] |
| positive regulation of cell population proliferation | biological process | Any process that activates or increases the rate or extent of cell proliferation. [GOC:go_curators] |
| positive regulation of heart rate | biological process | Any process that activates or increases the frequency or rate of heart contraction. [GOC:dph, GOC:tb] |
| positive regulation of glutamate secretion | biological process | Any process that activates or increases the frequency, rate or extent of the controlled release of glutamate. [GOC:ef] |
| myotube differentiation | biological process | The process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotube differentiation starts with myoblast fusion and the appearance of specific cell markers (this is the cell development step). Then individual myotubes can fuse to form bigger myotubes and start to contract. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse. [GOC:mtg_muscle] |
| calcium-mediated signaling | biological process | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. [GOC:signaling] |
| telencephalon development | biological process | The process whose specific outcome is the progression of the telencephalon over time, from its formation to the mature structure. The telencephalon is the paired anteriolateral division of the prosencephalon plus the lamina terminalis from which the olfactory lobes, cerebral cortex, and subcortical nuclei are derived. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, PMID:12626695] |
| positive regulation of cell growth | biological process | Any process that activates or increases the frequency, rate, extent or direction of cell growth. [GOC:go_curators] |
| positive regulation of prostaglandin biosynthetic process | biological process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin. [GOC:mah] |
| positive regulation of cellular pH reduction | biological process | Any process that activates or increases the frequency, rate, or extent of a process that reduces the internal pH of a cell. [GOC:mah] |
| social behavior | biological process | Behavior directed towards society, or taking place between members of the same species. Occurs predominantly, or only, in individuals that are part of a group. [GOC:jh2, PMID:12848939, Wikipedia:Social_behavior] |
| cellular response to water deprivation | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of water. [GOC:go_curators] |
| maternal behavior | biological process | Female behaviors associated with the care and rearing of offspring. [GOC:curators] |
| sperm ejaculation | biological process | The expulsion of seminal fluid, thick white fluid containing spermatozoa, from the male genital tract. [GOC:jl, http://www.cogsci.princeton.edu/~wn/] |
| response to corticosterone | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosterone stimulus. Corticosterone is a 21 carbon steroid hormone of the corticosteroid type, produced in the cortex of the adrenal glands. In many species, corticosterone is the principal glucocorticoid, involved in regulation of fuel metabolism, immune reactions, and stress responses. [PMID:15240347] |
| negative regulation of transmission of nerve impulse | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of transmission of a nerve impulse, the sequential electrochemical polarization and depolarization that travels across the membrane of a neuron in response to stimulation. [GOC:ai] |
| transport across blood-brain barrier | biological process | The directed movement of substances (e.g. macromolecules, small molecules, ions) through the blood-brain barrier. [GOC:aruk, GOC:bc, PMID:29377008] |
| G protein-coupled receptor signaling pathway | biological process | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor] |
| positive regulation of vasoconstriction | biological process | Any process that activates or increases the frequency, rate or extent of vasoconstriction. [GOC:go_curators] |
| cellular response to hormone stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus. [GOC:mah] |
| regulation of systemic arterial blood pressure by vasopressin | biological process | The regulation of blood pressure mediated by the signaling molecule vasopressin. Vasopressin is produced in the hypothalamus, and affects vasoconstriction, and renal water transport. [GOC:mtg_cardio, ISBN:0721643949] |